New results from the North American COVID-19 STEMI (NACMI) registry showed a 25% reduction in early mortality in 2021 compared to 2020 among STEMI patients with a confirmed COVID-19 infection.
The new recommendations went live just ahead of ACC.22. They can be read in full in the Journal of the American College of Cardiology, Circulation or Journal of Cardiac Failure.
One researcher described the findings, presented at the Heart Failure Society of America's Annual Scientific Meeting, as "great news for patients and clinicians."
This secondary analysis of data from the FIDELIO-DKD trial was presented May 17 at ACC.21 and published in the Journal of the American College of Cardiology.
Researchers explored data from the GALACTIC-HF trial to evaluate how the severity of a patient's reduced ejection fraction impacts the benefits of omecamtiv mecarbil.
FDA Commissioner Robert Califf, MD, explains the need for hospitals to perform quality assurance checks on clinical artificial intelligence to ensure these technologies don't "drift" from what was originally cleared by the FDA.
Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.
